Building political tensions between Russia and the West are making it increasingly difficult for drugmakers in the region, prompting Germany's Fresenius to dump a partnership there. The announcement comes as other drug companies have reported their businesses are under pressure in the area.
Roche is planning to make a major splash in China, looking to spend 450 million Swiss Francs ($466.2 million) to build a diagnostics operation in Suzhou.
Bristol-Myers Squibb is taking Gilead's lead when it comes to developing-world access for its hepatitis C drug, offering up a tiered pricing strategy and licensing agreements with generics makers. But according to some critics, that's not enough.
Chinese CRO WuXi PharmaTech has opened up shop in Israel, cutting the ribbon on a Tel Aviv outpost and aligning itself with a local investor to expand its presence in the country.
Unfortunately for foreign devicemakers, import substitution appears to be one of the means by which China intends to achieve its goal of creating 10 med tech breadwinners worth 5 billion yuan ($820 million) apiece by 2020.
Sanofi, which bought controlling interest in Dubai's Globalpharma in June, will kick off production there with generics of 6 of its drugs. Sanofi is now managing the facility.
Eli Lilly has published a how-to paper about its ambitious technology transfer program to help China, India, Russia and South Africa produce two drugs to treat multidrug-resistant tuberculosis. The bottom line is that the undertaking was harder than expected, and while it did not fully achieve all of its goals, it was worth doing.
Multinational pharma companies have been targeting China for years with an eye on its aging population, expanding middle class and growing incidence of chronic maladies like diabetes. So how are Germany's leading pharmas, Bayer and Merck KGaA, carving out an edge for themselves? Reputation, tech-sharing and cold, hard cash.
WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.
DKSH, a well-heeled pharma marketing operation, has reupped with Roche, expanding a long-standing agreement to include more of Asia.